Fundraising FoxFreemind Investments
Venture capitalBoston · Seed · 6 people tracked
Find your way into Freemind Investments
Sign up to find every way you can get introduced to Freemind Investments
- Your email: who you already know at Freemind Investments, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Freemind Investments team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Investment thesis
FMI is a life science investment platform that pairs an exclusive proprietary database of over 500 companies with a data-driven, de-risking investment formula. It evaluates opportunities at the intersection of a FreeMind organizational score, a federal scientific score, and business potential assessed through detailed due diligence by thousands of key opinion leaders. The fund reviews companies across all stages of development, with emphasis on pre-clinical and clinical-stage programs addressing human health conditions through therapeutics and medical devices. Beyond direct equity investment, FMI offers investees pharma deal-making opportunities including access to Asian markets, co-development, and partnerships. Deal flow is global with a strong emphasis on the US market.
Source: firm website, verified Oct 2, 2026.
Team · 6 people
from the firm's website
What they invest in
from 8 of 9 portfolio companiesBiotech ×7Healthtech ×5AI & Machine Learning ×3Deep Tech ×3Medical Devices ×2Digital Health ×1Longevity ×1
HQs:United States×7
Who they back
founder profiles across 5 portfolio companiesAccelerator rootsportfolio companies that came through a program
Investments · 9 tracked
founders shown can be your intro path
Abalone Bio develops target-activating antibodies for difficult-to-drug disease targets by combining engineered biology with machine learning.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Richard Yu(Founder)inGustavo Pesce(Founder)in
Co-investorsGravityHarmonix FundHorizons VenturesJude GomilaMetaplanetPioneer+4 more
BioKier develops oral products for managing lipids and glucose in type 2 diabetes and cardiometabolic disorders, designed to replicate the metabolic benefits of bariatric surgery through colon-targeted nutrient delivery.
BiotechHealthtechMedical DevicesChapel Hill, US
Jerzy R Szewczyk(Executive Officer, Director)Roger D Nolan(Executive Officer, Director)in
BoardJames Farrelly(Director)
Co-investorsBroadview Ventures
BiotechRockville, US
Jerry Parrott(Executive Officer, Director)in
BoardGlenn Miller(Director)Scott Allocco(Director)Katarzyna Kusmierz(Director)Douglas Clark(Director)Jack Davis(Director)
Co-investorsAbell Foundation, Inc.
General Proximity develops proximity-based technologies for drug discovery and development.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Armand Cognetta(Founder)in
Co-investorsY Combinatorage1Felicis VenturesLifespan Vision VenturesModi VenturesCoughdrop Capital+2 more
Renalis develops prescription digital therapeutics (PDTs), software applications that deliver evidence-based therapeutic interventions to patients under a clinician's care to prevent or treat medical disorders.
Digital HealthHealthtechMedical DevicesChicago, US
Missy Lavender(Executive Officer)in
Co-investorsJumpstart Ventures
BiotechBranford, US
John Richard Nobile(Executive Officer, Director, Promoter)John Davidson(Executive Officer, Director, Promoter)
Co-investorsConnecticut InnovationsLeading Edge Ventures
Thetis is a clinical-stage pharmaceutical company developing TP-317, an oral Resolvin E1 drug that activates the BLT1 receptor to restore tissue and immune balance.
BiotechHealthtechSouthport, US
Frank C Sciavolino(Manager)inGary Mathias(Co-Founder & CEO)inJohn Parkinson(Chief Science Officer)Joyce Steinberg(Chief Medical Officer)
BoardDavid M Wurzer(Manager)Alan Mendelson(Manager)
Co-investorsConnecticut Innovations
Vincere Biosciences develops small-molecule therapeutics targeting mitochondrial quality control and mitophagy, primarily for neurodegenerative diseases including Parkinson's disease.
AI & Machine LearningBiotechDeep TechLongevity
Co-investorsAlumni VenturesBeiersdorf Innovation FundBeresford VenturesDraper AssociatesPortal InnovationsquadraScope Venture Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Renalis Health
Frequently asked questions
- How many investments has Freemind Investments made?
- Freemind Investments has 9 tracked investments.
- What stage does Freemind Investments invest at?
- Freemind Investments invests at the Seed stage.
- What sectors does Freemind Investments focus on?
- Freemind Investments focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Freemind Investments located?
- Freemind Investments is headquartered in Boston, US.
- Who does Freemind Investments co-invest with?
- Freemind Investments most often shares deals with Y Combinator, Connecticut Innovations, Draper Associates, among 20 tracked co-investors.
Similar investors
Merck Global Health Innovation Fund (MGHIF) is the corporate venture arm of Merck & Co., investing in digital health and data science companies that support and optimize biopharmaceutical operations to improve patient care.
Seed Healthcare is a firm focused on disrupting healthcare through early disease detection and prevention, offering investment capital and advisory services to healthcare companies.
Easton Capital is a venture capital fund focused on healthcare and life sciences, backing capital-efficient companies whose products or services improve care or reduce costs.
SV Health Investors is a global private equity and venture capital platform dedicated to healthcare, running specialized funds across biotechnology (including dementia), healthcare growth equity, and medtech.
Kicker Ventures invests in technology-driven healthcare companies developing novel solutions to health challenges, ranging from biosignal detection and data science to AI-driven personalized engagement.